RxDoctor Payments Data

Bikram Soni, MD

Cardiovascular Disease · Selma, CANPI 1508836727

Payments from drug & device makers

$4,830in general payments, 2019–2025

Across 244 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Biotronik Inc.$816
  • Merck$455
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$434
  • Novartis$358
  • Amarin Pharma, Inc.$309
  • plus $1K from 27 others

What the payments were for

  • Travel & lodging$65714%
  • Food & beverage$4,09885%
  • Gifts$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,830 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$514,189
Medicare patients
1,269
Services billed
4,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban258$242,997
EntrestoSacubitril/Valsartan174$181,340
XareltoRivaroxaban60$65,919
Repatha SureclickEvolocumab44$33,270
VascepaIcosapent Ethyl56$30,637
FarxigaDapagliflozin Propanediol33$26,793
Ranolazine ErRanolazine54$6,214
Metoprolol Succinate452$6,187
Icosapent Ethyl17$6,153
Ezetimibe74$4,103
Atorvastatin Calcium351$3,981
Rosuvastatin Calcium170$2,932
ClopidogrelClopidogrel Bisulfate256$2,781
Nifedipine ErNifedipine53$2,232
Pravastatin Sodium140$2,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$242,997258 claims
NovartisEntresto$358$181,340174 claims
Johnson & JohnsonXarelto$141$65,91960 claims
AstraZenecaFarxiga$71$26,79333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Selma

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →